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ABSTRACT 
Establishment and validation of a novel Fucci (fluorescent ubiquitination-based cell cycle 
indicator) in an in vitro chronic myeloid leukemia model  
Jane Marie Isquith 
The deregulation of the cell cycle is important in the leukemic transformation and 
in the continued discovery of more efficient targeted therapies.  After elucidation of the 
role of the RNA editor ADAR1 in the malignant reprogramming of Chronic Myeloid 
Leukemia (CML) progenitors to leukemia stem cells (LSCs) during the chronic phase to 
blast crisis stages of the disease, current research seeks to uncover the mechanism of 
action of ADAR1 in this process. To study the potential role ADAR1 plays in the 
changes to cell cycle during this disease progression, a novel Fucci (fluorescent 
ubiquitination-based cell cycle indicator) system was introduced into the CML cell line 
K562 through stable transduction of both Fucci vectors.  This allows for the visualization 
of the cell cycle via FACS (fluorescence activated cell sorting), and fluorescent live 
imaging.  This system was validated for use in therapeutic CML research through 
preliminary evaluation of ADAR1 activity in specific cell cycle stages as well as the 
effects of a potentially novel CML therapy, 8-azaadenosine, on the cell cycle. 
Completion of this work shows successful creation of a novel generation of  Fucci cell 
line; which will aid in the  clarification of the changes which occur in the cell cycle 
during CML disease progression, as well as the effects of CML targeted therapies on cell 
cycle regulation though quantitative and qualitative analysis.  
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CHAPTER 1 
Literature Review 
1.1 Introduction  
The study of cancer stem cells (CSC) and their role in the disease transformation 
and progression is at the forefront of research being conducted in the field of leukemia. 
According to the Centers for Disease Control and Prevention, cancer is the second 
leading cause of death in the United States.  Leukemia is defined as a cancer of the blood 
or bone marrow and is categorized by four major subsets, distinguished by the affected 
lineage and severity: acute myeloid leukemia (AML), acute lymphocytic leukemia 
(ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).  
The American Cancer Society report that CLL constitutes about one third of leukemia 
diagnoses. While the other manifestations of leukemia affect older people, ALL is most 
prevalent in children.  There will be approximately 6.000 new cases of ALL in 2013, 
about one third affecting adults.  CML accounts for approximately 10% of all new 
leukemia diagnoses, and it is estimated that there will be almost 6,000 new diagnoses in 
2013.  New cases of AML are estimated to be approximately 14,500.   
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1.2 Acute and Chronic Myeloid Leukemia 
While there exist similarities between AML and CML, the disease state and 
subsequent malignancy is driven through different molecular events.  These differences 
are key to understanding the future of targeted therapies.  AML can be seen as the more 
severe, end-stage prognosis, whereas CML undergoes a potentially slower progression 
through three stages: chronic phase, accelerated phase and blast crisis [1].  CML has also 
been described as biphasic, in which chronic phase and blast crisis are the two 
manifestations of the disease [2]. The malignancies of each stage of CML differ slightly, 
and it is crucial to note that blast crisis CML possesses great similarities to AML [3]. 
AML phenotypically presents as an excess of immature hematopoietic cells, known as 
leukemic blasts, which do not possess the characteristics of a cell type likely to allow for 
metastasis of the disease [4]. This finding gave rise to the work toward elucidating the 
population of cells responsible for propagation of the cancerous cells [4]. Unlike AML, 
CML undergoes a progression of the disease from chronic phase (CP) to the terminal 
blast crisis (BC) stage. Blast crisis closely resembles AML, with an accumulation of 
immature blasts with enhanced self-renewal capacity and worsening prognosis [5, 6].  
After progression from CP to BC, life expectancy drops dramatically to approximately 6 
months [7].  CML was the first cancer to be defined at the molecular level when the 
reciprocal translocation of chromosome 9 and 22 was identified, which results in the 
generation of the Philadelphia chromosome (Ph
+
). This chromosomal abnormality was 
first discovered and studied in leukemia in 1960 by Nowell and colleagues, and further 
characterized into the next decade [8, 9].  Upon translocation there is the creation of the 
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BCR/ABL tyrosine kinase fusion protein [5, 10, 11].  This 210 kD oncogenic fusion 
protein, which is also referred to as P210
bcr/abl
,  leads to unregulated activity of the 
tyrosine kinase signaling cascade, and effects such as unchecked proliferation [11].  
Based on the work examining the molecular pathogenesis of the leukemic transformation, 
it seems evident that this translocation can occur at the level of one hematopoietic stem 
cell (HSC); and this now malignant progenitor undergoes clonal expansion to facilitate 
the aberrant leukemic phenotype [11, 12].  
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1.3 Cancer Stem Cells  
Elucidation of the cancer stem cell (CSC) population in leukemia was first studied 
in AML by John Dick and colleagues in the 1990’s. Through these experiments, a 
definition for CSCs in AML was established characterizing the population of cells in 
AML which are capable of maintenance and metastasis of leukemia.  As in normal stem 
cells, these cells possess the ability to self-renew and differentiate, allowing propagation 
of the disease as demonstrated by in vivo studies in which both primary and secondary 
transplantation of the hypothesized CSC population isolated from human AML patients 
yielded the same AML disease state [4].  Subpopulations of leukemic cells can be 
identified by their expression of cell surface proteins. The two markers now commonly 
used for the identification of leukemia stem and progenitor populations are the surface 
proteins CD34 and CD38.  While the functions of these proteins are still somewhat 
elusive, it is known that CD34 plays a role in cell adhesion as well as hematopoietic stem 
cell (HSC) trafficking [13]. While CD 34
+ 
cells are known to have the ability to 
reconstitute the hematopoietic system in patients undergoing bone marrow 
transplantation [14].   CD38 is also a transmembrane glycoprotein, which also belongs to 
a family of cytosolic and membrane bound enzymes that catalyze nicotinamide adenine 
dinucleotide (NAD) reactions [15, 16].  It has also been shown to function in calcium 
mobilization and signaling [17].  In both of these manifestations of leukemia, the CSC 
population is known to be CD34
+ 
CD38
- 
, in comparison with the progenitor population, 
which are known to have double positive expression of these markers, therefore making 
them CD34
+ 
38
+ 
. These two populations are distinct based on the capacity of the 
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CD34
+
CD38
- 
 population to self-renew, whereas in AML the CD34
+
CD38
+ 
population 
does not [7]. The method of identifying the potential for malignant populations of 
cancerous cells to self-renew is demonstrated through the transplantation of cell 
populations identified by their marker expression in mouse models. Cell populations that 
are able to engraft into host animals and initiate disease are in that way validated as being 
capable of potentiating the disease [18, 19].  These cells can also be identified in vitro 
nature through colony assay studies involving the re-plating of cells in culture to classify 
self-renewal [20].   
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1.4 BCR-ABL signaling  
Upon translocation, creation of the BCR-ABL1 oncogene results in translation of 
the Bcr-Abl fusion protein, which resides solely in the cytoplasm, as compared to normal 
Abl which is found in both the nucleus and cytoplasm. This translocation also causes the 
constitutive activation of the Abl tyrosine kinase and subsequent deregulation and 
oncogenic activity of this signaling pathway [21]. This aberrant signaling is manifested 
through the apposition of the Bcr and Abl protein, causing constitutive activation of Abl 
signaling through dimerization and tetramerization and subsequent activation of 
downstream signaling [21-23].  Signaling activated or promoted by Abl activation 
includes PKC, RAC, RAS, PI3K and Jak cascades [24].  Very early studies in CML 
showed that the origins of the disease can begin at the level of a single hematopoietic cell 
[25, 26].  The ensuing expansion of the leukemic clone is hypothesized to lead to 
progression of the disease, however new research is showing there may be multiple other 
factors involved in regulation and advancement of the disease [5, 11, 27].  CML is 
characterized phenotypically by the rapid growth and expansion of  a specific subset of 
CD34
+
CD38
+  
hematopoietic progenitor population known as the granulocyte 
macrophage progenitor (GMP) population (CD45RA
+ 
CD123
+
), which leads to an 
unchecked accumulation of other myeloid cells [28].  These myeloid progenitor cells 
leave the bone marrow niche prematurely, and subsequently lead to the accumulation in 
the blood, along with an increased number of mature cells as well [2, 11].  In comparison 
to AML in which there is unchecked growth and expansion of immature cells, CML 
chronic phase (CP) exhibits abnormal numbers of more mature cells [5, 7]. In 
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concurrence with most other forms of cancer, CML expansion is characterized by 
unregulated proliferation and differentiation, as well as changes in the quiescent 
population [10]. This expression pattern resembles that of normal stem cells, leading to 
the hypothesis that there may be factors driving these propagating cells towards 
malignancy.  Blast crisis CML is driven by the leukemia stem cell (LSC) population, 
which manifests phenotypically as overexpansion of an abnormal GMP population.  
These leukemic cells now possess an uncharacteristic ability for self-renewal, while 
exhibiting a less mature phenotype, as seen by the massive accumulation of these 
immature progenitor cells [7, 29].   
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1.5 Current Treatments: Tyrosine Kinase Inhibitors 
Current treatments of CML target the effects of the BCR-ABL fusion oncoprotein 
with tyrosine kinase inhibitors (TKI) including imatinib and dasatinib, which 
mechanistically function to inhibit the deleterious and oncogenic downstream effects of 
this unregulated kinase pathway.  While this targeted therapy has shown success in 
patients with CML CP, many patients undergoing treatment with these drugs will initially 
exhibit or develop a clinical resistance [30, 31]. Abl kinase inhibitors have been shown to 
inhibit the in vitro effects of unchecked kinase activity such as cellular proliferation, as 
well as in vivo dose dependent inhibition of tumor growth [32]. These kinase inhibitors 
function as a competitive inhibitor to the ATP binding site of the Abl kinase [1]. Imatinib 
prevents BCR-ABL activity by binding the inactive conformation and prohibiting the 
transition into the active form [6, 33]. Also important to this breakthrough therapy is its 
selective nature as demonstrated by its ability to target activity of only Bcr-Abl 
expressing cells. In addition it does not show deleterious effects on normal hematopoiesis 
[1, 32].  Imatinib (also known as Gleevec or STI571) was the first generation Bcr-Abl 
kinase inhibitor, shown to function to achieve a complete cytogenic response (CCR); a 
state defined as eradication of Ph
+ 
cells in the bone marrow [7]. Despite this success via 
treatment with first generation TKIs such as imatinib, some patients exhibit a primary 
resistance, in which there is no initial cytogenic response to treatment; or a secondary 
resistance in which patients lose their initial response to imatinib. The most common and 
well defined cause of this resistance is due to BCR-ABL mutations. Numerous amino acid 
mutations affecting the kinase domain of the protein have been characterized, leading to 
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the inability of the drug to bind [6, 34].  It is also hypothesized that this may be in part 
due to the reliance on the CSC and progenitor population in the progression of CML, 
although the mechanism by which quiescent LSC remain resistant to treatment is not 
fully defined [10].  Studies have shown that the quiescent CD34
+ 
population can survive 
through treatment of imatinib, whereas the most affected population of cells are those that 
are dividing [35].  Dasatinib, the second generation SRC/BCR-ABL kinase inhibitor, has 
been shown to be more potent than imatinib, however resistance can still be developed, 
and after treatment, there seems to be minimal reduction in the quiescent population [30, 
36]. Dasatanib has a slightly different mechanism of action than its predecessor; this 325-
fold more potent TKI binds a similar region of the ATP binding domain in the active 
conformation of BCR-ABL [6, 37]. The CSC or progenitor population of cells may be 
resistant to these targeted therapies and therefore contribute to the reemergence of the 
disease after treatment, as indicated by the ability to achieve a CCR through imatinib 
treatment followed by the reemergence of the disease [38].  Studies conducted by the 
Jamieson lab are looking into possible explanations for what drives the growth and 
maintenance of these CSCs in order to find advanced therapies for more effective 
prediction and prevention of CML progression.  
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1.6 RNA Editing and ADAR1 
The role of the CSC and progenitor populations in CML is crucial to 
understanding the mechanisms for propagation and potential therapeutic targets.  The 
exposition of the mechanisms maintaining the stem-like qualities of these cells is at the 
forefront of CML research.  Besides the ability for self-renewal and differentiation, there 
seems to be deregulation of the cell cycle, and an exaggerated quiescence in these stem 
and progenitor cells [10, 30].  Studies have been conducted examining the mechanisms of 
action by which cells acquire these new found characteristics ideal for the promotion of 
metastasis. The missplicing of GSK3β has been shown to distinguish BC from CP CML 
[39].  Aberrant splicing can also lead to the generation of oncoproteins, including 
generation of novel protein isoforms which can be tumorigenic or play a role in the 
development of therapeutic resistance [40].  The identification of these abnormalities in 
RNA processing has generated much interest in the role of RNA regulatory pathways in 
cancer initiation and progression. One mechanism responsible for this promotion of a 
malignant progenitor through RNA modification may be the effects of RNA editing 
specifically by the adenosine deaminase acting on double stranded RNA (ADAR) 
editases.  RNA editing is classically defined as the change in coding properties of RNA, 
through the modification of nucleotide sequence [41, 42].  ADAR was first identified in 
Xenopus laevis in 1987 and was subsequently studied in other organisms [43] There are 
three forms of ADAR in mammals (ADAR1, ADAR2, and ADAR3); however ADAR1 is 
the most highly characterized in hematopoietic cell development and this form is the 
focus of studies in our lab.  ADAR1 is present in two isoforms; a 150 kDa interferon 
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inducible protein (p150) that is found in both the nucleus and the cytoplasm, as well as a 
truncated 110 kDa protein (p110) that localizes solely to the nucleus [44, 45].  ADAR1 
has been shown to edit RNA extensively in primate-specific Alu sequences through 
adenosine-to-inosine (A-to-I) editing with a variety of post-transcriptional changes. Alu 
elements are non-coding retrotransposons that account for more than 10% of the human 
genome [46]. The A-to-I change in nucleotide sequence is recognized functionally as an 
A-to-G change [47].  Results of this editing include creation of alternative splicing sites 
[44, 48] as well as changes to RNA structure [42, 49].  Alternative splicing can create 
multiple protein transcripts from a single gene, which has already been indicated in 
cancer biology through the generation of novel oncogenic isoforms; as is the case with 
the missplicing of GSK3β.  RNA editing by ADARs on Alu sequences has also been 
shown to occur at high frequency during embryonic development [50].  ADAR1 has also 
been linked specifically to the survival of hematopoietic progenitor cells [51, 52].  In this 
work, hematopoietic progenitor cells only propagated and survived to be found in bone 
marrow and peripheral blood when knockdown of the Adar allele was not induced.  This 
logically leads to the supposition that ADAR editing may play a crucial role in cancer, 
and specifically in CML. This hypothesis is supported by findings of increased ADAR1 
expression in other forms of cancer, including astrocytomas [53].  The latest work done 
in the Jamieson lab by Jiang, et al (PNAS, 2013) has linked ADAR1 p150 expression to 
CML disease progression and the malignant transformation of progenitors to leukemia 
stem cell (LSC) like cells. This works shows increased ADAR1 p150 in CP CML 
compared to normal cord blood and a subsequent significant increase as the disease 
progresses to BC. ADAR1 is also known to have distinct effects on the cell cycle; 
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specifically overexpression of ADAR1 leads to the acceleration of the cell cycle as well 
as the proportional decrease of cells in G0 and G1 cells paired with an increase in S phase 
cells.  The proposed mechanism of this accelerated cell cycle is through the upregulation 
and activity of cyclin dependent kinase 2 and it’s corresponding cyclin A, which naturally 
accumulates in S phase of the cell cycle. [54]. Therefore, elucidation of the changes that 
occur in the cell cycle of CML cells, both in general and due to the effects of ADAR1, is 
crucial to furthering the understanding of CML initiation and progression.   
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1.7 8-azaadenosine  
After elucidation that ADAR1 does in fact play a role in the blastic transformation 
[55], research can be focused on examining the numerous possible mechanisms of action 
through which ADAR1 could function.  8-azaadenosine is a compound that can be 
chemically synthesized and has been shown to be a substrate for adenosine deamination 
by ADAR2 [41, 56]. ADAR2 resides in the same family of ADAR enzymes as ADAR1, 
and have similar editing activity, however there are some differences in editing site 
preference [57, 58].  8-azaadenosine has been shown to incorporate into polynucleotides 
as 8-azaadenine and 8-azaguanine [59].  8-azaadenosine has also been studied in cancer 
research, and examined as an anti-tumor agent in human colon carcinoma cell lines [60].  
It has also been proposed to also cause cell death through inhibition of DNA synthesis 
[59], so future studies will be necessary to distinguish between effects of this inhibitor on 
RNA editing and DNA alterations. Based on these factors, work with 8-azaadenosine in 
CML will seek to elucidate the effects of 8-azaadenosine on ADAR1 activity and cell 
cycle regulation in CML. 
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1.8 Cell Cycle and the Fucci System  
While it has been a common technique to examine cell proliferation using cell 
tracking dyes such as carboxy-fluorescein diacetate succinimidyl ester (CFSE) that labels 
parent cells but becomes diluted upon generation of daughter cells. There are, however, 
alternative methods to investigate not only the general proliferation activity but also to 
study the distinct phases of the cell cycle.  This is of importance in the field of CML 
research due to the fact that there is most like aberrant manifestations of the cell cycle in 
cancerous cells.  The Fucci system (fluorescent ubiquitination-based cell cycle indicator) 
is an emerging tool that can be used to examine the cell cycle in numerous applications.  
This system exploits two distinct proteins that are ubiquitinated at different stages of the 
cell cycle by fusing them with either green or red fluorescent tags [61]. This system was 
set up after previous research illuminated the oscillating ubiquitination by E3 ubiquitin 
ligases controlling the different transitions throughout the cell cycle [62].  The fluctuation 
of these ligases throughout the cell cycle regulates the degradation of proteins that control 
transitions from one stage of the cell cycle to the next.  Cyclin-dependent kinases (CDK) 
regulate these transitions and are active dependent on the accumulation of stage specific 
cyclins which facilitate entry into a specific stage, or alternatively inhibit exit from a 
stage [63, 64].  This requires changes in cyclin levels throughout the cell cycle, so that 
there is a logical progression through each stage.  Cyclins, and other proteins involved in 
the regulation of the cell cycle, are marked for degradation through ubiquitination [64].   
There are three components that work  in conjunction to mark proteins for degradation 
via ubiquitin mediated proteolysis, E1 ubiquitin activating enzymes, E2 ubiquitin 
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conjugating enzymes, and E3 ubiquitin ligases; E3 ubiquitin ligases being the enzyme 
that is responsible for the covalent attachment of ubiquitin to the protein of interest [65]. 
There are two prevalent E3 ubiquitin ligases, anaphase promoting complex (APC) and 
SKP1-CUL1-F-box-protein complex (SCF), function through feedback loops to show 
reciprocal activity during late M/G1 and S/G2 phases, respectively [64].  In the original 
generation of these probes, a direct substrate of SCF
skp2
,
 
Cdt1, was fused to mKO2 
(monomeric kusabira orange 2). Since SCF
skp2
 is the E3 ubiquitin ligase that 
polyubiquitinates Cdt1, which marks it for degradation, Cdt1 shows accumulation (and 
subsequent red fluorescence) during the G1 phase of the cell cycle.  Geminin, which is 
ubiquitinated by APC
cdh1
, was similarly fused to mAG (monomeric Azami Green) 
leading to accumulation of green fluorescence in S/G2/M, as APC
cdh1 
is active during G1. 
This progression of the ubiquitination linked fluorescence therefore also exhibits yellow 
fluorescence during the G1/S transition, as Cdt1 accumulates during G1 and the geminin 
begins to no longer be degraded in S phase, there is an overlap in the presence of both 
proteins [61]. and is colorless when cells are in G0 [61].  In the second generation of 
Fucci vectors, mCherry (which displays red fluorescence) was fused to Cdt1 and mVenus 
(which displays green fluorescence) was fused to Geminin to allow for a sharper color 
contrast between cell cycle phases.  Upon cell death, the cell membranes become 
permeable, and as these vectors are not tightly bound, fluorescence is lost through the 
compromised membranes [66]. In the experiments describing the generation of these 
second generation constructs, lentivirus was created through co-transfection of the 
vectors encoding either mCherry-hCdt1 or mVenus-hGem and then transduced into HeLa 
or NMuMG cell lines and selected via single cell cloning or FACS.  In the experiments 
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conducted in the Jamieson lab, we employed a similar technique of lentiviral transduction 
using two different vectors; one encoding mCherry-hCdt1 and the other mVenus-hGem 
and sorted for stable transduction by FACS.  These second generation Fucci lentiviral 
reporters were used to investigate cell cycle regulation in CML cell lines. These vectors 
can be introduced into cell lines using lentiviral transduction establishing stable lines 
which can be used to elucidate the changes in the cell cycle in progressive stages of CML 
as well as the effects of current and novel therapies on the cell cycle.  Examining how 
CML therapies modify the cell cycle is crucial to the development of combination 
therapies to prevent the emergence of therapeutic resistance.  The development of the 
Fucci system in CML models will allow for advances in targeted therapy of CML.  This 
system can be used to sort populations of cells in different phases of the cell cycle in 
order to study the effects of novel treatments.  
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1.9 Conclusion and Relevance  
Cumulative evidence demonstrates a role for abnormal ADAR1-mediated RNA 
editing and cell cycle deregulation [67] in CML progression, underscoring the need for 
more in-depth analysis of these processes and the connection between aberrant RNA 
editing and cell cycle control in CSC and other malignant cell populations. The elegant 
design of the Fucci vector system allows for in vitro analysis of these processes using 
CML cell lines.  In this context, the main hypothesis of this project is to be able to 
investigate the changes in cell cycle regulation in CML initiation and progression through 
introduction of a Fucci system into a CML cell line. Thus, the overall goal of this project 
was to develop an optimized protocol for transducing cells with multiple Fucci vectors in 
order to visualize and quantify the cell cycle.  The use of splicing and adenosine 
deaminase inhibitors in combination with current CML therapies is currently under 
investigation for use as potential CML therapies.  There is substantial interest concerning 
the effects of these potential treatments on the cell cycle.  It remains a crucial element of 
CML research to identify if there is a therapy that can target the quiescent cell population 
or conversely a factor that can drive those quiescent cells into cycling normally so that 
current treatments will have a more profound and lasting effect.  The secondary objective 
of this project was to validate the effects of potential anti-CSC therapies in a Fucci CML 
cell line model using a putative ADAR1 inhibitor- 8-azaadenosine, on the cell cycle 
regulation in a CML.  
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CHAPTER 2 
ESTABLISHMENT AND VALIDATION OF A NOVEL FUCCI (FLUORESCENT 
UBIQUITINATION-BASED CELL CYCLE INDICATOR) IN AN IN VITRO 
CHRONIC MYELOID LEUKEMIA MODEL  
 
2.1 Introduction 
Despite advances in recent decades that have introduced molecularly-targeted 
therapies for chronic myeloid leukemia (CML), the molecular events driving leukemic 
transformation and disease progression of CML remain poorly-defined and require 
further elucidation for advances to be made in translational medicine.  CML is classically 
defined by the expression of the BCR/ABL fusion oncoprotein caused by the reciprocal 
translocation of chromosome 9 and 22, resulting in the formation of the Philadelphia 
chromosome [5, 10, 11]. This translocation and oncoprotein generation causes the 
constitutive activation of the Abl tyrosine kinase and subsequent deregulation and 
oncogenic activity of this signaling pathway [21]. The ensuing expansion of the leukemic 
clone possessing the BCR/ABL mutation is hypothesized to lead to progression of the 
disease, however new research is showing there may be other factors involved in 
regulation and advancement of the disease. These include additional mutations such as in 
the Jak/STAT signaling cascade, specifically in JAK2, as well as subsequent triggers of 
cellular deregulation [5, 11, 27, 68, 69].  
Previous research recently published by the Jamieson lab has shown that the RNA 
editing enzyme ADAR1 (adenosine deaminase acting on RNA-1) is involved in the 
progression of CML from chronic phase (CP) to blast crisis (BC).  Expression of one 
specific inflammation-responsive ADAR1 isoform, ADAR1 p150, has been linked to 
CML disease progression and the malignant transformation of progenitors to leukemia 
stem cell (LSC) like cells [55]. ADAR1 is known to edit primarily Alu repeat sequences 
through adenosine-to-inosine (A-to-I) editing.  The numerous downstream effects of this 
editing include changes in cell proliferation and differentiation [54].  
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Changes in the cell cycle are known to occur during the leukemic transformation 
as well as disease progression in CML.  There has been great interest pertaining to the 
deregulation of the cell cycle and the quiescent population of leukemic stem cells (LSCs).  
LSCs have been indicated in being at least partially responsible for the transformation of 
CML from CP to BC; notably due to the inherent quiescent subpopulation of LSC.  This 
population is able to propagate the disease through asymmetric division leading to the 
production of a quiescent daughter cell as well as one able to differentiate into a mature 
cancerous cell [70]. LSCs and the quiescent population of cells in any cancer, including 
CML, play a key role in development of therapeutic resistance, because they are often not 
affected by current anti-cancer treatments [10]. After the elucidation of ADAR1 activity 
in CML disease progression, the specific roles of ADAR1 can be examined. We carried 
out a series of experiments in leukemic cells engineered to express high levels of ADAR1 
p150 to further investigate the role of ADAR1 in leukemic progression. We observed 
qualitative changes in cells overexpressing ADAR1 in both a CML cell line, K562, and 
corresponding alterations in primary CML patient samples transduced with a lentiviral 
vector overexpressing ADAR1 p150.  These changes include cell size as well as cell 
proliferation.  Based on these findings we hypothesize that increased ADAR1 expression 
in CML affects the cell cycle potentially being one of the mechanisms by which ADAR1 
modulates blastic transformation of CML.   
To study the cell cycle in CML, a current commonly used method employs 
immunostaining and flow cytometry for cell cycle analysis.  However, visualization is 
limited to assessment of cell surface protein marker expression. In this study, we show a 
novel system that allows for visualization and isolation of cells at individual phases of the 
cell cycle, and creates a method in which to study in vitro the effects of CML therapies 
on cell cycle. 
The Fucci system (fluorescent ubiquitination-based cell cycle indicator) is an 
emerging tool that can be used to examine the cell cycle in numerous applications by 
using two complexes that have ubiquitination activity at different stages of the cell cycle 
and fusing them with either green or red fluorescent tags [61].  This system has been 
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shown to be effective in studying changes in the cell cycle caused by anticancer drugs in 
normal cell lines [61], but has yet to be studied in an in vitro CML model.  In this work, 
the establishment of the Fucci system in the CML cell line K562 is validated through 
FACS analysis, confocal imaging, as well as preliminary tests of a novel therapeutic 
agent and putative ADAR1 inhibitor, 8-azaadenosine.   
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2.2 Materials and Methods 
Cell Culture 
All cell lines were maintained at 37° C, 5% CO2
   
and supplemented with 
corresponding complete media as per product recommendations. K562, LAMA84, 
LAMA87 and KU812 cell lines were purchased from ATCC (Manassas, VA).  K562 
were grown in DMEM supplemented with 10% FBS (Gemini Bio-Products, Sacramento, 
CA), 1% Glutamax (Life Technologies, Carlsbad, CA), and 1% NEAA.  LAMA84 and 
KU812 were grown in RPMI 1640 (Life Technologies, Carlsbad, CA) supplemented with 
10% FBS.  LAMA87 were grown in RPMI 1640 with 20% FBS supplementation. Cells 
were maintained at approximately 70-80% confluence.  For multi area time lapse images, 
complete media was supplemented with 1:100 penicillin/streptomycin.  In some 
experiments, a stromal co-culture system was used to more closely emulate the normal 
bone marrow environment (Figure 2). Murine SL and M2 cell lines were maintained in 
culture separately until use in co-culture experiments. SL cells were grown in DMEM 
supplemented with 10% FBS, 1% L-glutamine, 1% NEAA and 1:100 
penicillin/streptomycin. M2 cells were grown in RPMI supplemented with 10% FBS, 1% 
L-glutamine, and 1:100 penicillin/streptomycin. Both cell lines were split approximately 
once per week using 0.25% trypsin; SL cells were split 1:10, M2 cells were split 1:20.  
Every five passages, transgenic clones were selected by culturing for one passage in 1X 
G418 and 1X Hygromycin.(Life Technologies, Carlsbad, CA).  One day before co-
culture, cells were trypinized and collected in a 50 mL tube, washed with complete 
media, and resuspended in 1X mitomycin-C (0.01mg/mL) and incubated for 3 hours at 
37
o 
C.  After incubation cells were washed with PBS and plated 1:1.  After 24 hours, 
SL/M2 media was aspirated and K562 cells were added in corresponding media.   
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Viral Transduction 
Primary Transduction 
To increase transduction efficiency and initial cell survival, cells were transduced 
with the two vectors independently.  After creation of a stable Fucci-R-transduced 
population, Fucci-M transduction was performed on this single positive population. All 
cell lines were transduced first with lentiviral Fucci-R expressing mCherry. A 100μl cell 
suspension was plated into 10 wells of a 96-well plate. Concentrated Fucci-R virus (made 
by the UCSD Sanford Consortium for Regenerative Medicine viral vector core) was 
diluted in each line’s corresponding media and 5μl of diluted virus was added to each 
well. Cells were then incubated for 3-5 days and mCherry expression was monitored by 
fluorescence microcopy.  
After 3-5 day incubation with the virus in 96 well plates, cells were collected and 
transferred into 2 wells of a 6 well plate per condition. These were expanded 1-2 days 
then transferred into a T75 flask for continued propagation.  Cells were expanded until 
reaching a desired volume for sorting, usually ≥ one T75 flask.  At the time of sorting, 
cells were collected by centrifugation, washed with HBSS plus 2% FBS and then sorted 
for mCherry expression using a BD FACSAriaII. Only live cells were selected by 
resuspending cells in a 1:1000 pI solution and gated for pI negative cells only.  Cells with 
high red fluorescence intensity were sorted into 1mL FBS with 20% 
penicillin/streptomycin and kept on ice until transfer into warm complete media.  To 
increase survival, this primarily sorted population of cells were plated at a density of 
>30% confluence in a corresponding volume container.  In most cases, after primary 
sorting, cells were plated into a 6-well plate for initial expansion.  Once cells reached 
approximately 80% confluence they can be transferred to larger plates or flasks for 
expansion. 
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Secondary Transduction 
After expansion of Fucci-R positive cells, 100μl of cells were plated into 10 wells 
of a 96 well plate.  Concentrated Fucci-M lentivirus (supplied by the UCSD Sanford 
Consortium for Regenerative Medicine viral vector core) was diluted with RPMI 1640 
supplemented with 20% FBS and 5μl diluted virus was aliquoted to each well.  Cells 
were incubated for 3 days before collected and transferred to a 6-well plate.  Cells were 
maintained in culture and expanded until reaching an appropriate confluence to sort. Live 
cells were sorted for either mVenus expression or expression of both mCherry and 
mVenus, which presented at a yellow emission caused by the overlap of the two 
fluorophores. This population was then expanded for subsequent experiments.  Stable 
transduction was monitored by fluorescence expression. 
 
Cell Cycle Sorting 
After development of the stably transduced K562-Fucci cell line, cells were sorted 
based on fluorescence determined by the Fucci system on the BD FACSAriaII using 
DAPI as a live/dead indicator. Colorless cells were sorted as cells in G0; Fucci R positive 
cells (mCherry only) were sorted as G1 cells; Double positive cells expressing both 
mCherry and mVenus were sorted as cells in the G1/S transition; and cells expressing 
only FucciM (mVenus only) were sorted as cells in G2.  Cells were sorted into 2mLs 
FBS with 1:100 penicillin/streptomycin. Cells were then immediately plated in K562 
complete media or frozen in 90% FBS, 10% DMSO. These were thawed directly into 
K562 complete media for live cell imaging of synchronized cell populations. 
 
Live Imaging 
Confocal and time lapse images were taken using a computer-assisted Olympus 
Fluoview FV10i fluorescence microscope (Olympus America, Center Valley, PA).  Cells 
were plated at low densities in normal culture media. Cells were maintained at 37
o 
C, 5% 
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CO2 in the incubation chamber of the microscope for extended imaging. For time lapse 
imaging, cells were plated into 35mm, 14mm microwell with no. 1.5 coverglass (0.16-
0.19mm) Poly-d-lysine coated culture dishes (MatTek Corporation, Ashland, MA). 
Images were taken at 5 minute intervals, for varied amounts of time no less than 24 hours 
to ensure documentation of cell division.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Page 25 
2.3 Results  
Stable transduction of Fucci-R and Fucci-M 
The CML cell line K562 was successfully stably transduced with both Fucci-R 
and Fucci-M lentiviral vectors, and has maintained expression of the two vectors for 
greater than 20 passages. Stable transduction was assessed by FACS sorting based on 
fluorescence; followed by regular monitoring with a fluorescence microscope (Figure 1). 
Over numerous subcultures, no loss of fluorescence activity was detected.  The other cell 
lines, LAMA 84, LAMA 87, and KU 812 were successfully transduced with a single 
vector but due to the stringent selection process ensuring that all selected cells have been 
transduced, they were never expanded to the density required for secondary transduction 
(results not shown). Future work can be performed to create double positive stable 
transduction in these cell lines.    
 
ADAR1 expression in K562  
K562 Fucci R-M cells were sorted on a BD FACSAria II to isolate single 
populations of cells in different stages of the cell cycle using the Fucci system (Figure 2).  
The populations of interest that we are able to sort are G0, which are colorless; G1, which 
express only mCherry; cells in the G1/S transition during which time both markers are 
expressed, leading to an overlap in the two fluorophores; and also G2/M, in which there 
is solely mVenus expression.  This technique presents not only a method of sorting cell 
stages of interest, but it also allows for synchronization of cell populations. This is 
especially useful in cell lines where this presents a challenge as other techniques such as 
nutrient starvation is not sufficient for synchronization, as seen in our own experiments.  
After sorting, we were able to extract RNA and perform qPCR assessing the expression 
of ADAR1 in each specific population.  These preliminary findings showed no 
distinguishable differences in ADAR1 isoform expression in any stage of the cell cycle, 
but did allow us to show that we can in fact analyze specific cell stages for expression of 
markers of interest (Figure 3).   
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Effects of 8-azaadenosine on K562 
To further validate the K562 Fucci system for use with CML therapies, as well as 
to test the effects of a potential therapeutic agent, we examined the effects of 8-
azaadenosine on the CML cell line K562 both by FACS analysis as well as through long-
term, multi area live imaging (Figure 4).  A titration of varying concentrations of 8-
azaadenosine was performed on K562 Fucci cells in normal culture conditions.  After 5 
days of treatment, cells were analyzed on the FACSAriaII.  We sought to identify which 
concentration of 8-azaadenosine caused cell death or proliferation, as well whether 8-
azaadenosine was responsible for any other alterations in the cell cycle, such as a shift or 
arrest of cells into a particular cell cycle stage.  The results of this experiment indicate 
that as compared to the vehicle (DMSO) only control, low levels of 8-azaaddenosine (≤ 
100nM) stimulate an apparent increase in cell numbers, however a large population of the 
cells remain in G0, with an normal comparative distribution of cells in the other cell cycle 
stages. At the two highest concentrations of 8-azaadenosine (1,000nM and 10,000nM), 
there is noticeable cell death accompanied by a shift in the proportion of cells in each 
stage of the cell cycle.  This is seen as a dramatic decrease in the number of cells in G0, 
along with an increase in the proportion of cells in the G1/S transition.   
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2.4 Discussion  
In this series of experiments, successful establishment of the Fucci system in the 
CML cell line K562 has been performed and validated for use in in vitro studies.  This 
novel construction was adapted from the original protocol for use in our CML model.  
The model provides an important new tool for elucidation of the role of cell cycle 
modifications in the process of leukemic transformation, as well as the continued efforts 
to enhance the efficacy of targeted therapies. Although it will be of great relevance to 
adapt this model into primary patient samples, it was necessary to first optimize the 
protocol in a well-documented, and clinically relevant cell line. The BCR-ABL+ K562 
cell line is used as an in vitro model of CML, and while displays some of the typical 
drawbacks encountered when using a cell line, it remains useful in preliminary 
experiments as well as a control to use for comparison to primary CML patient samples.  
This K562 Fucci line can also be used in preliminary drug screenings, as patient samples 
are too valuable to use in protocol optimizations such as establishing ideal drug 
concentrations for use as a possible combination therapy to treat CML.    
We were able to establish a stably double positive Fucci R-M K562 cell line and 
validate it through FACS analysis, long-term confocal live cell imaging, and preliminary 
drug screening.  For these experiments, we began the process of examining ADAR1, a 
RNA editor which we have previously described as playing a role in the leukemic 
transformation. One goal of our studies focuses on determining the effects of ADAR1 
activity on the cell cycle, and whether deregulation of the cell cycle is a possible 
mechanism of action by which ADAR1 drives blastic transformation. Previous findings 
revealed by the Jamieson lab show that ADAR1 overexpression promotes blastic 
transformation through the reprogramming of progenitor cells into LSCs [55].  Because 
the cell cycle plays such a crucial role in the fate of LSCs in the maintenance of 
quiescence, we sought to explore novel methods of studying the changes that occur in the 
cell cycle during leukemic transformation.  In experiments using enforced overexpression 
of ADAR1 in both K562 as well as primary patient samples, we observed qualitative 
changes in cellular proliferation and size.  This observation, along with other publications 
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describing the role of ADAR1 in cell cycle as well as documentation that the cell cycle is 
deregulated in CML, we extended our studies in elucidating the role of ADAR1 in cell 
cycle changes in CML. While previous studies have examined the effects of 8-
azaadenosine in other types of cancer, it has not been evaluated in CML. In these early 
studies involving 8-azaadenosine, the compound was shown to cause cell death through 
inhibition of DNA synthesis, and therefore induces antitumor effects [59, 60].  In 
corroboration with our findings, we saw that while treatment seems to drive cells into the 
G1/S transition, they do not successfully divide; which could be explained by the 
previous research showing 8-azaadenosine inhibits successful DNA synthesis [60]. At the 
two higher concentrations (1,000nM and 10,000nM) of 8-azaadenosine, there is 
significant cell death, however it is interesting to note that the surviving cells displayed a 
noticeable shift into the G1/S transition.  There is a lower number of cells in G0 as 
compared to the control as well as the lower three concentrations of 8-azaadenosine.  
This suggests that while the cells may be actively cycling, they do not divide or 
proliferate normally.   
Due to the development of clinical resistance in some CML patients after 
treatment with standard tyrosine kinase inhibitors (TKI), and the likelihood of this 
resistance leading to the reemergence of the disease in the deadly BC manifestation, there 
is ever increasing focus in the entire realm of CML research as well as our lab to develop 
therapeutic strategies to overcome this resistance.  The results of these preliminary 
experiments suggest that a combination therapy approach may be the most effective; with 
one agent keeping cells in an active stage of the cell cycle so that another cytotoxic 
compound could be used to kill the cancerous cells.  In clinical CML research there are 
many therapies that are known to target cells in different stages of the cell cycle, however 
the need remains for a compound that will drive cells out of G0, as cells in this stage are 
mostly unaffected by current drugs and therefore primed for development of resistance.   
After optimization of in the Fucci system in the K562 cell line, the next steps in 
this research remain to expand the use of this model system into patient samples, which 
will allow assessment that more closely models what occurs in vivo. Limitations for the 
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use of the Fucci system in primary patient samples include overcoming double positive 
transduction efficiency in samples with limited cell numbers. We anticipate that only a 
small fraction of double-positive cells will be able to be isolated, due to the fact that we 
encounter cell loss after each sort because of the selection process ensuring sufficient 
transduction.  In a cell line, this presented as only a minor setback as these cells will 
continue to proliferate in almost any condition; however it is known that patient samples 
do not proliferate nearly as rapidly (if at all) and are often unstable in culture conditions, 
and cells do not survive if not provided with the right culture conditions. Co-transduction 
with both vectors at the same time could be considered, however determination of dually 
transduced cells could be difficult, and again would not entirely overcome the inherent 
loss of cells during selection. 
Continued research is being conducted in our lab to advance the development of 
the Fucci system for continued use in vitro and in vivo.  By cloning in different 
fluorescent colors, this system can be used in conjunction with overexpression vectors, as 
well as in in vivo live imaging.  We will also continue work with this generation of the 
K562 Fucci cell line in work examining the role of ADAR1 in cell cycle regulation, as 
well as other facets of our CML research including testing new therapies, such as a 
selective Jak2 inhibitor, and investigating the ways in which they modulate the cell cycle.  
Through continued work with this K562 generation of Fucci vectors, future work 
includes examining the effects of new and current CML therapies on synchronized 
populations of cells, such as the effects of 8-azaadenosine on the quiescent G0 
population.  This will allow us to further examine the effects of quiescence on the 
development of resistance, as well as develop new strategies for therapies targeting 
cancerous cells in specific stages of the cell cycle.  
In conclusion, this work has resulted in the generation and validation of a novel 
Fucci vector system in a CML cell line.  Further experimentation will allow for the 
elucidation of the specific changes that occur in the cell cycle during leukemic 
transformation, progression, and therapeutic resistance of CML. This model can also be 
used for preliminary drug screenings and investigating the potential for using 
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combination therapies targeting cells in specific stages of the cell cycle. Optimization of 
this protocol establishing the Fucci system in our CML cell line has also advanced work 
towards using this model in vivo for more physiologically relevant modeling of CML.  
Work with this system can be used for continued research focusing on overcoming the 
development of resistance to current CML therapies, which could ultimately lead to 
identification of a more effective and lasting cure for CML and other CSC-driven 
malignancies. 
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A)  
 
B) 
 
 
 
C) 
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Fig. 1. Establishment of a stably double positive Fucci R-M K562 cell line. K562 
cells were expanded in normal culture conditions and transduced with lentiviral Fucci 
vectors in two series of transductions. A) Fucci-R transduction was performed first, 
followed by fluorescence sorting and expansion of mCherry positive cells. B) Fucci-R 
positive cells were then transduced with Fucci-M, and subsequently sorted for mVenus 
fluorescence expression.  C) This population of cells shows retention of fluorescence 
throughout subculture and expansion as seen by fluorescence microscopy on an Olympus 
CXK41 with a) showing the overlay of red and green fluorescence and b) the same 
population with phase contrast. 
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Fig. 2. Analysis of the cell cycle using the Fucci system.  This novel Fucci K562 
cell line was analyzed based on the fluorescence indicators associated with this system.  
The x-axis represents the intensity of red fluorescence, whereas the y-axis represents the 
intensity of green fluorescence.  Colorless cells seen in quadrant 1 (Q1) are expressing 
none of the labeled ubiquitination markers and are therefore in G0 of the cell cycle.  Q2 
shows cells expressing only mCherry, indicating G1 stage.  Double positive cells 
exhibiting expression of both mCherry and mVenus indicates the overlap of the two 
fluorophores and the G1/S transition.  After the G1/S transition, mCherry expression is 
lost, and mVenus positive cells indicate G2 as well as M stage (Q4).  
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Fig. 3. ADAR1 expression in K562 cells in specific stages of the cell cycle. Double 
positive K562 Fucci-R/M cells were sorted by FACS for the four stages of the cell cycle 
based on the properties of the Fucci system. Relative ADAR1 expression was analyzed 
by RT qPCR using human specific ADAR1 primers for both ADAR1 p150 (P150) and 
ADAR1 p110 (P110).  No qualitative differences in either ADAR1 isoform expression. It 
appears that there is a decrease in ADAR1 mRNA expression in the G1/S transition, 
however results are not conclusive. It should be noted that this is just preliminary data 
validating the Fucci system for use in CML research, and that relative abundance of 
ADAR1 in different stages of the cell cycle could be different in primary samples as 
compared to this cell line, due to the fact that n=1 for this experiment.  The results of this 
experiment indicate that the Fucci system can be used in conjunction with FACS sorting 
to generate distinct populations of cells in specific stages of the cell cycle that can be 
used for subsequent experimentation.    
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B) 
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C) 
 
Fig. 4. Effects of 8-azaadenosine titration on cell cycle. K562 Fucci cells were treated with 
a titration of a novel therapeutic agent, 8-azaadenosine for 5 days before analysis by 
FACS. Cells were plated in 12-well plates at a density of 5x10
4
, treated with each 
corresponding dose of 8-azaadenosine (or DMSO as a vehicle only treatment).  A) FACS 
plots show the distribution of cells in each stage of the cell cycle. The progression of the 
cell cycle can be seen in a counter-clockwise progression; quiescent G0 cells show no 
fluorescence therefore are located in the bottom left quadrant. The reciprocal activity of 
the two major E3 ubiquitin ligases results in the accumulation of two distinct cell cycle 
regulatory proteins at different stages of the cell cycle.  As cells cycle and express 
accumulation of the Cdt1 protein in G1 they exhibit red fluorescence.  The G1/S 
transition is marked by the overlap of the two fluorophores.  G2 through M phases are 
marked by the accumulation of the geminin protein and green fluorescence.  B)  Graph 
showing the percentages of cells in each stage of the cell cycle.  Results seem to indicate 
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a shift from quiescence to active cycling. C) Following the titration experiment, cells 
were subjected to 24 hour treatment with 10,000nM 8-azaadenosine and imaged 
continuously using a computer assisted Olympus confocal microscope.  Images captured 
at 5 minute intervals allow for visualization of the cells progressing through the cell 
cycle. Image shown is a still taken from an early time point and shows cells in G1 (red 
fluorescence) and G2/M (green fluorescence).  Dead cells present colorless (as well as 
displaying not normal morphology), as when the cell membrane becomes permeable 
upon death, fluorescence is no longer contained in the cell.  
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